We are live on
!
Find out more
TD Asset Management Portfolio holdings
AUM
$115B
1-Year Est. Return
41.58%
This Fund
S&P 500
This Quarter
Est. Return
+8.84%
1 Year Est. Return
+41.58%
3 Year Est. Return
+119.77%
5 Year Est. Return
+143.7%
10 Year Est. Return
+448.76%
AUM
$82.9B
AUM Growth
+$1.82B
(+2.3%)
Cap. Flow
-$3.2B
Cap. Flow
% of AUM
-3.86%
Top 10 Holdings %
Top 10 Hldgs %
27.48%
Holding
1,503
New
58
Increased
633
Reduced
567
Closed
76
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Merck
MRK
|
+$256M |
| 2 |
State Street Energy Select Sector SPDR ETF
XLE
|
+$169M |
| 3 |
Eli Lilly
LLY
|
+$156M |
| 4 |
Franco-Nevada
FNV
|
+$115M |
| 5 |
NVIDIA
NVDA
|
+$115M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Canadian Pacific Kansas City
CP
|
+$990M |
| 2 |
Pfizer
PFE
|
+$226M |
| 3 |
Amazon
AMZN
|
+$224M |
| 4 |
Johnson & Johnson
JNJ
|
+$220M |
| 5 |
Alphabet (Google) Class C
GOOG
|
+$220M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.76% |
| 2 | Financials | 19.43% |
| 3 | Healthcare | 10.94% |
| 4 | Consumer Discretionary | 8.03% |
| 5 | Communication Services | 7.27% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1026
Celldex Therapeutics
CLDX
$3.07B
| $1.65M | ﹤0.01% |
45,761
-9,500
| -17% | -$410K |
|
1027
Interparfums
IPAR
$4.12B
| $1.64M | ﹤0.01% |
11,500
-11,000
| -49% | -$1.36M |
|
1028
Encore Capital Group
ECPG
$2.05B
| $1.63M | ﹤0.01% |
32,356
+2,800
| +9% | +$146K |
|
1029
Alignment Healthcare
ALHC
$2.8B
| $1.59M | ﹤0.01% |
250,504
+20,682
| +9% | +$197K |
|
1030
Amplitude
AMPL
$1.31B
| $1.59M | ﹤0.01% |
127,438
+64,200
| +102% | +$853K |
|
1031
Texas Capital Bancshares
TCBI
$4.41B
| $1.58M | ﹤0.01% |
32,348
-12,286
| -28% | -$755K |
|
1032
Carlisle Companies
CSL
$15.3B
| $1.58M | ﹤0.01% |
7,003
+123
| +2% | +$29.9K |
|
1033
Huron Consulting
HURN
$2.43B
| $1.58M | ﹤0.01% |
19,606
-1,200
| -6% | -$87.2K |
|
1034
Coca-Cola Consolidated
COKE
$12B
| $1.57M | ﹤0.01% |
29,320
| – | – |
|
1035
Darling Ingredients
DAR
$9.56B
| $1.56M | ﹤0.01% |
26,757
-96
| -0.4% | -$6.04K |
|
1036
MACOM Technology Solutions
MTSI
$20.9B
| $1.56M | ﹤0.01% |
+22,000
| New | +$1.49M |
|
|
CYBR
1037
DELISTED
CyberArk
CYBR
| $1.56M | ﹤0.01% |
10,513
-488
| -4% | -$68.2K |
|
1038
Okta
OKTA
$25.7B
| $1.52M | ﹤0.01% |
17,673
-848
| -5% | -$64.6K |
|
|
HCNE
1039
DELISTED
Jaws Hurricane Acquisition Corp. Class A Common Stock
HCNE
| $1.52M | ﹤0.01% |
150,000
| – | – |
|
|
AXON
1040
Axon Enterprise
AXON
$48.9B
| $1.52M | ﹤0.01% |
6,767
+4,196
| +163% | +$834K |
|
1041
Interactive Brokers
IBKR
$39.5B
| $1.51M | ﹤0.01% |
73,340
-2,716
| -4% | -$55.3K |
|
|
ABST
1042
DELISTED
Absolute Software Corp
ABST
| $1.51M | ﹤0.01% |
192,871
-268,676
| -58% | -$2.62M |
|
1043
First American
FAF
$7.76B
| $1.51M | ﹤0.01% |
27,060
| – | – |
|
|
FBMS
1044
DELISTED
The First Bancshares, Inc.
FBMS
| $1.5M | ﹤0.01% |
58,090
+5,800
| +11% | +$171K |
|
1045
Red Rock Resorts
RRR
$3.76B
| $1.5M | ﹤0.01% |
33,606
+12,800
| +62% | +$566K |
|
|
HSII
1046
DELISTED
Heidrick & Struggles
HSII
| $1.49M | ﹤0.01% |
49,200
+15,100
| +44% | +$462K |
|
1047
Caleres
CAL
$479M
| $1.49M | ﹤0.01% |
69,000
+52,800
| +326% | +$1.27M |
|
|
TPH
1048
DELISTED
Tri Pointe Homes
TPH
| $1.49M | ﹤0.01% |
58,900
| – | – |
|
1049
Signet Jewelers
SIG
$3.78B
| $1.48M | ﹤0.01% |
19,000
-2,100
| -10% | -$156K |
|
1050
Resources Connection
RGP
$158M
| $1.48M | ﹤0.01% |
86,500
+42,000
| +94% | +$737K |
|
Similar funds
VAM
TD Asset Management's Q1 2023 Portfolio in Review
As of Q1 2023, TD Asset Management held 1,503 positions worth $82.9B, up 2.3% from $81B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
TD Asset Management withdrew a net $3.2B in Q1 2023, closing 76 positions and reducing 567 holdings. Its most notable exit was Canadian Pacific Kansas City, an estimated $990M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, up from 17% a quarter earlier, followed by Financials and Healthcare.
Against the trend, TD Asset Management opened a new position in Novo Nordisk worth $25.2M.
- TD Asset Management's largest Q1 2023 buy was Novo Nordisk: 316,140 shares worth $25.2M.
- TD Asset Management added most to Merck in Q1 2023, an estimated $256M increase.
- TD Asset Management's biggest Q1 2023 reduction was Pfizer, cutting an estimated $226M.
- TD Asset Management fully exited Canadian Pacific Kansas City in Q1 2023, selling an estimated $990M.
- TD Asset Management's ten largest holdings make up 27% of its $82.9B portfolio in Q1 2023.
- TD Asset Management opened 58 new positions and closed 76 in Q1 2023.
- TD Asset Management's portfolio value rose 2.3% quarter-over-quarter to $82.9B.
Based on TD Asset Management's 13F filing for Q1 2023, filed 10 May 2023.